Pharma & Bio
Technology
Y-Bio Bets on Its Own Pipeline… Aims for Early Technology Transfer with Triple-Antibody
#Y-Biologics is aiming for early-stage technology transfer in the preclinical phase, leveraging its proprietary trivalent antibody.Y-Biologics is shifting its focus from an antibody platform company t…
Manufacturing
‘From Low-Molecular-Weight Compounds to Antibody Platform’: Abion Advances Its Business... Also Pursuing Additional Technology Transfers
#Abion is seeking to transform itself from a new drug development company into an antibody platform company. While Abion has previously focused on developing new small-molecule drugs, it is now upgrad…
Lifestyle
Semiconductor Rally Dominates...But Profit-Driven JLK and DT&CRO Surge on Solid Earnings [K-Bio Pulse]
As capital continued to flow into the semiconductor sector in the domestic stock market, the biotech and medical technology sectors also saw steady valuation gains, particularly among companies backed…
Lifestyle
Amid a Strong Semiconductor Market, JLK and DT&CR Rise on Strong Earnings [Bio Spotlight]
Amid the ongoing concentration of investment in the semiconductor sector in the domestic stock market, the biotech sector has also shown a steady upward trend in value, led by companies with solid ear…
Business·Industry
PinoBio Smiles as Celltrion’s Clinical Trials Progress Smoothly… Aims for Three New Technology Transfers This Year
PinoBio, a developer of antibody-drug conjugates (ADCs), is aiming to secure up to three new technology transfer deals by the end of the year. This is because PinoBio is currently engaged in meaningfu…
Business·Industry
'ADC All-Rounder' Kanap Therapeutics: A Top Performer in the Technology Transfer Relay
Kanap Therapeutics, a newcomer that listed on KOSDAQ in March of this year, possesses the capability to independently develop all components of antibody-drug conjugates. Kanap Therapeutics is attracti…
Technology
Yang Gil-an, CEO of CoaStem ChemOn: “U.S. Regenerative Medicine Institution Proposed Collaboration First… Accelerating Expansion into the U.S.”
“We didn’t knock on the U.S. door. U.S. regenerative medicine research institutions approached us first.”Yang Gil-an, CEO of #CoastemChemOn, recently spoke with PharmEdaily—Edaily’s premium pharmaceut…
Lifestyle
GI Innovation and Orient Bio Surge on Strong Data and Governance [K-Bio Pulse]
While foreign and institutional capital continues to be heavily concentrated in the semiconductor sector of the South Korean stock market, the biotechnology segment successfully held its ground on Jun…
Lifestyle
Amid Continued Concentration in Semiconductors, G.I. Innovation and Orient Bio Show Performance and Accountability, Shares Rise [Bio Spotlight]
Amid a persistent trend of foreign and institutional investors heavily concentrating their funds in the semiconductor sector in the domestic stock market recently, the biotech sector managed to hold i…
Technology
Shin Seong-seop, Executive Vice President of KSBL: “We Will Compete in the Global Market for Nano-Anticancer Drugs by Integrating Technology, Production, and Sales Networks”
“KSBL aims to compete in the global market by integrating technology, production, and sales networks, particularly in the field of complex generics—which are difficult to manufacture—and specifically …